Provided by Tiger Trade Technology Pte. Ltd.

Amgen

407.27
-14.2400-3.38%
Post-market: 407.990.7170+0.18%19:57 EDT
Volume:2.50M
Turnover:1.03B
Market Cap:219.31B
PE:25.30
High:422.80
Open:421.72
Low:407.13
Close:421.51
52wk High:447.03
52wk Low:283.00
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.86
T/O Rate:0.47%
Dividend:9.80
Dividend Rate:2.41%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:18.76
PE(LYR):28.62

Loading ...

Piper Sandler Keeps Their Buy Rating on Amgen (AMGN)

TIPRANKS
·
Sep 23

Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating

MT Newswires Live
·
Sep 23

Scotiabank Sticks to Its Buy Rating for Amgen (AMGN)

TIPRANKS
·
Sep 23

Amgen Underperform Maintained as Dazodalibep Data Uncertainty Limits Upside; $317 Price Target Unchanged

TIPRANKS
·
Sep 23

US Research Roundup- Allstate, Autozone, Vertex Pharmaceuticals

Reuters
·
Sep 23

Amgen Inc. Stock Advances 4.3%, Outperforms Peers

Dow Jones
·
Sep 23

Aytu BioPharma Q4 Revenue Beats Analyst Estimates on EXXUA Sales

Reuters
·
Sep 23

Update: US Equity Indexes, Crude Oil Prices Mixed in Midday Trading

MT Newswires Live
·
Sep 23

U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify

Reuters
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)

TIPRANKS
·
Sep 22

Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement

TradingKey
·
Sep 22

Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi

TIPRANKS
·
Sep 22

Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal

Reuters
·
Sep 22

Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial

Reuters
·
Sep 22

Movement Alert|Amgen Rises 3.39% in Regular Trading, Dazodalibep Phase 3 Trial in Sjogren Disease Delivers Positive Results

Market Focus
·
Sep 22

Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial

THOMSON REUTERS
·
Sep 22

Movement Alert|Amgen Rises 4.79% in Pre-Market Trading, Dazodalibep Phase 3 Trial in Sjogren Disease Delivers Positive Results

Market Focus
·
Sep 22

Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease

Reuters
·
Sep 22

Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease

THOMSON REUTERS
·
Sep 22

Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity

THOMSON REUTERS
·
Sep 22